Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of a placebo and edoxaban. Edoxaban is an oral anticoagulant classified as a direct factor Xa inhibitor. It works by selectively inhibiting factor Xa, an essential enzyme in the coagulation cascade, thereby preventing the formation of blood clots. Edoxaban is primarily indicated for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, as well as for treating deep vein thrombosis (DVT) and pulmonary embolism (PE) after initial therapy with a parenteral anticoagulant[1][2][6][7]. The "placebo" component refers to an inert substance with no pharmacological effect, commonly used in clinical trials to serve as a control.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on placebo + edoxaban.